###begin article-title 0
###xml 43 48 <span type="species:ncbi:9606">Human</span>
Prion Protein Expression and Processing in Human Mononuclear Cells: The Impact of the Codon 129 Prion Gene Polymorphism
###end article-title 0
###begin p 1
Conceived and designed the experiments: CS JJC. Performed the experiments: CS. Analyzed the data: CS SL JJC. Contributed reagents/materials/analysis tools: SL. Wrote the paper: CS JJC.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 103 109 <span type="species:ncbi:9913">Bovine</span>
So far, all clinical cases of new variant Creutzfeldt-Jakob disease (vCJD), thought to result from the Bovine Spongiform Encephalopathy (BSE) prion agent, have shown Methionine-Methionine (M/M) homozygosity at the M129V polymorphism of the PRNP gene. Although established, this relationship is still not understood. In both vCJD and experimental BSE models prion agents do reach the bloodstream, raising concerns regarding disease transmission through blood transfusion.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 110 115 <span type="species:ncbi:9606">human</span>
We investigated the impact of the M129V polymorphism on the expression and processing of the prion protein in human peripheral blood mononuclear cells (PBMCs) from three blood donor populations with Methionine-Methionine (M/M), Valine-Valine (V/V) and M/V genotypes. Using real-time PCR, ELISA and immunoblot assays we were unable to find differences in prion protein expression and processing relating to the M129V polymorphism.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
These results suggest that in PBMCs, the M129V PrP polymorphism has no significant impact on PrP expression, processing and the apparent glycoform distribution. Prion propagation should be investigated further in other cell types or tissues.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 171 174 171 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Pocchiari1">[1]</xref>
###xml 176 179 176 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Prusiner1">[2]</xref>
###xml 243 246 243 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Will1">[3]</xref>
###xml 515 517 515 517 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 587 588 587 588 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 588 591 588 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Prusiner2">[4]</xref>
###xml 596 597 596 597 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 605 607 605 607 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 650 653 650 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Stahl1">[5]</xref>
###xml 679 682 679 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Turk1">[6]</xref>
###xml 733 736 733 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Endo1">[7]</xref>
###xml 738 741 738 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Haraguchi1">[8]</xref>
###xml 803 806 803 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Stahl2">[9]</xref>
###xml 885 886 885 886 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 922 924 918 920 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 969 973 962 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Caughey1">[10]</xref>
###xml 974 978 967 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Safar1">[12]</xref>
###xml 1117 1119 1110 1112 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 1152 1153 1145 1146 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 1206 1210 1199 1203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Moroncini1">[13]</xref>
###xml 1386 1390 1379 1383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Cohen1">[14]</xref>
###xml 1392 1396 1385 1389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Caughey2">[15]</xref>
###xml 1454 1455 1447 1448 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 1547 1548 1540 1541 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 1591 1595 1584 1588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Taraboulos1">[16]</xref>
###xml 1638 1646 1631 1639 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1664 1665 1657 1658 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 1674 1676 1667 1669 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 1692 1696 1685 1689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Lehmann1">[17]</xref>
###xml 1722 1723 1715 1716 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 2009 2013 2002 2006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Chen1">[18]</xref>
###xml 2363 2367 2356 2360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Pan2">[19]</xref>
###xml 125 130 <span type="species:ncbi:9606">human</span>
###xml 289 295 <span type="species:ncbi:9913">Bovine</span>
Transmissible spongiform encephalophathies (TSEs or prion diseases) are fatal neurodegenerative disorders, of which the main human form is Creutzfeldt-Jakob disease (CJD) [1], [2]. Importantly, a new variant of CJD (vCJD) has recently emerged [3], believed to result from oral exposure to Bovine Spongiform Encephalopathy (BSE). Although the exact nature of the infective agent remains controversial, many believe that infectivity is closely associated with the accumulation of a pathological misfolded protein, PrPSc (Scrapie Prion Protein), derived from the normal cellular protein PrPC[4]. PrPC and PrPSc isoforms share the same primary structure [5]: a single disulfide bond [6], two complex-type N-Linked oligosaccharide chains [7], [8], and a C-terminal glycosyl phosphatidylinositol (GPI) anchor [9]. The difference between the isoforms relates to their secondary structure: PrPC is rich in alpha-helices, while PrPSc has a higher content of beta-pleated sheets [10]-[12]. During prion propagation, the increase in the level of infectivity is associated in most cases with the accumulation of the misfolded PrPSc protein, believed to convert PrPC through a pathological conformational rearrangement [13]. Although the mechanism explaining this transconformation remains unclear, two different models have been proposed: nucleation-polymerization and template-assisted conversion [14], [15]. Both involve the recruitment of normal prion protein PrPC. Biochemical studies in cultured cells demonstrate that conformational rearrangement of PrPC can occur in the absence of glycosylation [16] and that N-glycan chains can modulate the in vitro conversion of PrPC into PrPSc-like molecules [17]. In the normal brain, PrPC processing includes proteolysis of the full-length protein to generate a main N-terminal truncated protein named the C1 fragment. However, proteolysis can also generate an additional, longer C-terminus protein -the C2 fragment - that accumulates in prion-infected brain in particular. [18].The C2 fragment only accumulates as a resistant truncated protein in CJD-affected brains. This raises questions about whether this truncated form influences the possibility of developing the illness. Moreover, studies have described the accumulation of under-glycosylated, full-length and N-Terminal truncated PrP as a fingerprint for prion disease [19].
###end p 9
###begin p 10
###xml 82 86 82 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Lee1">[20]</xref>
###xml 233 237 233 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Alperovitch1">[21]</xref>
###xml 397 401 397 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-1">[22]</xref>
###xml 508 510 508 510 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 536 540 536 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Kretzschmar1">[23]</xref>
###xml 542 546 542 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Moser1">[24]</xref>
###xml 586 590 586 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Peden1">[25]</xref>
###xml 618 620 618 620 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 693 697 693 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Hill1">[26]</xref>
###xml 698 702 698 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Klein2">[29]</xref>
###xml 837 842 837 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 842 846 842 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Houston1">[30]</xref>
###xml 1435 1439 1435 1439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Pincock1">[31]</xref>
###xml 1440 1444 1440 1444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Turner1">[33]</xref>
###xml 1823 1827 1823 1827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Ironside1">[34]</xref>
###xml 2090 2091 2090 2091 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 2158 2161 2158 2161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Prusiner2">[4]</xref>
###xml 2163 2167 2163 2167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Taraboulos1">[16]</xref>
###xml 2169 2173 2169 2173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Lehmann1">[17]</xref>
###xml 2175 2179 2175 2179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Harris1">[35]</xref>
###xml 2267 2268 2267 2268 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 2318 2319 2318 2319 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 2434 2435 2434 2435 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 2513 2517 2513 2517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Barclay1">[36]</xref>
###xml 2519 2523 2519 2523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Barclay2">[37]</xref>
###xml 35 40 <span type="species:ncbi:9606">human</span>
###xml 495 503 <span type="species:ncbi:9606">patients</span>
###xml 605 613 <span type="species:ncbi:9606">patients</span>
###xml 935 940 <span type="species:ncbi:9940">sheep</span>
###xml 963 969 <span type="species:ncbi:9606">humans</span>
###xml 985 993 <span type="species:ncbi:9606">patients</span>
###xml 1157 1165 <span type="species:ncbi:9606">patients</span>
###xml 1458 1464 <span type="species:ncbi:9606">person</span>
###xml 1664 1672 <span type="species:ncbi:9606">patients</span>
The PRNP gene, on the short arm of human chromosome 20, encodes the prion protein [20]. Some polymorphisms of the PRNP open reading frame (ORF) seem to be involved in susceptibility to different forms of CJD (iCJD, gCJD, sCJD, vCJD) [21]. This is illustrated by the fact that 100% of the clinical vCJD cases thus far have been Methionine -Methionine homozygous at the M129V polymorphism (129-M/M) [22], yet only 40% of the Caucasian population carry this genotype. Importantly, in classical CJD patients, PrPSc accumulates in neuronal, [23], [24] follicular dendritic cells, and muscle [25], but for vCJD patients, PrPSc also accumulates in lymphoid tissue, including the tonsils and appendix [26]-[29]. This distribution raised concerns about blood transfusion from the very beginning of the epidemic. Since then, studies by Houston F. et al[30] have demonstrated that prion transmission by blood transfusion occurs experimentally in sheep infected with BSE. In humans, three UK vCJD patients had previously been transfused with red cells donated by individuals who subsequently developed vCJD 1.5-3.5 years after donation. All three transfusion-recipient patients carried the 129-M/M genotype. A fourth recipient of red cells from a donor who later developed vCJD, died from unrelated causes. Post mortem investigation in this case found abnormal prion accumulation in the spleen and in one cervical lymph node, but not in the brain [31]-[33]. Recently, a person with hemophilia who died of a condition unrelated to vCJD, only showed evidence of infection with the abnormal prion protein in the spleen at post mortem. In these cases without clinical signs, both patients were heterozygous 129-M/V. This bears in mind the sub-clinical CJD cases with 129-V/V recently described in a retrospective study of appendix samples [34]. Polymorphism at position 129 could, therefore, not only influence susceptibility to prions, but also impact the incubation time or clinical onset of the disease. One possible mechanism to explain this relation would be the consequence of 129 polymorphism on PrPC expression and processing that are critical for prion propagation [4], [16], [17], [35]. Given the concerns regarding vCJD transmission through blood transfusion, studying PrPC in blood seems particularly relevant. Indeed, PrPC distribution determined by ELISA and flow cytometry, shows that plasma mononuclear cells and platelets express PrPC, although contradictory results were obtained for red cells and granulocytes [36], [37].
###end p 10
###begin p 11
###xml 113 114 113 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 269 270 269 270 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 294 295 294 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
In order to investigate a possible relationship between the M129V polymorphism and susceptibility to vCJD and PrPC expression, we compared three blood donor populations of different genotypes: M/M, M/V, and V/V at position 129. We analyzed their expression of total PrPC (mRNA, protein) and PrPC isoforms (glycosylated and truncated proteins) in peripheral blood mononuclear cells (PBMCs).
###end p 11
###begin p 12
Our results showed that in these cells, PrP expression and processing did not determine susceptibility to prion disease.
###end p 12
###begin title 13
Materials and Methods
###end title 13
###begin title 14
Blood Samples
###end title 14
###begin p 15
After having obtained informed consent in writing from each blood donor, in compliance with the French law (code de la sante publique article L.1243-3), whole blood was taken in EDTA collection tubes. Given the well known distribution of codon M129V genotypes (41% M/M, 49% M/V and 10% V/V) in the French population, the study did not require the approval of the Bioethical Review Board. We genotyped a total of 119 donors in order to obtain a statistically representative V/V population.
###end p 15
###begin title 16
Isolation of peripheral blood mononuclear cells (PBMCs)
###end title 16
###begin p 17
###xml 261 262 261 262 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 950 951 950 951 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 103 108 <span type="species:ncbi:9606">human</span>
In order to avoid bias due to physiological variation in the percentage of granulocytes (40 to 70%) in human blood, we examined only purified mononuclear cells. Indeed, preliminary studies performed on leukocyte populations (data not shown) indicate a lower PrPC mRNA expression in granulocytes than mononuclear cells. Consequently, we only purified mononuclear cells from blood by centrifugation through a Ficoll-Hypaque gradient (Pharmacia, 91 898 Orsay, France). In brief, whole blood diluted Vol./Vol. with phosphate-buffer saline (PBS) was carefully layered upon Ficoll and spun at 700 g. Mononuclear cells were harvested from the interface of the plasma-platelets layer and the Ficoll, washed in PBS and suspended in the same buffer. The cell suspension was analyzed in triplicate, on the ABX (Beckman Coulter, 95942 Roissy, France) hemocytometer for total cell number and mononuclear cell purity level. After elimination of PBS, aliquots of 106 PBS-cleared PBMCs were stored at -80degreesC.
###end p 17
###begin title 18
RNA extraction
###end title 18
###begin p 19
###xml 100 101 100 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
Total RNA was isolated (High Pure RNA isolation kit, Roche Diagnostics, 38240 Meylan France) from 106 PBMCs, according to the manufacturer's instructions. Briefly, cells were lysed by solubilizing them in lysis/binding buffer optimized for RNA extraction (4,5M guanidin hydrochloride, 50 mM Tris-HCl and 30% Triton X-100, pH 6.6). Homogenized lysate was then transferred to a filter tube for binding to the fiberglass filter. After centrifugation at 10 000 g for 15 sec, residual contaminated DNA was digested by DNase I (180 U/tube) applied directly to the fiberglass filter and incubated for 15 min. After washing three times - in order to eliminate enzymes and cellular impurities - purified RNA was eluted with 50 microl elution buffer (nuclease-free sterile water), and immediately stored at -80degreesC.
###end p 19
###begin p 20
As the PRNP ORF sequence is located on only one exon, to exclude potential contamination by genomic sequences, we treated total RNA extracts with RNase-free DNase before amplification. Samples were then controlled for the absence of genomic sequence by performing PCR directly on the RNA extracts, thus avoiding the reverse transcription step.
###end p 20
###begin title 21
cDNA synthesis
###end title 21
###begin p 22
The first cDNA strand was synthesized by reverse transcription (R.T. at 42degreesC for 1 hour) from 5 microl of RNA (preheated for 7 min at 70degreesC) in the presence of hexanucleotides (7 microM), dNTPs (800 microM each), 60 U Rnasin Ribonuclease Inhibitor (Promega, 69260 Charbonnieres France) and 300 U M-MLV-RT (Promega) in a final volume of 35 microl. cDNA was then purified with "High Pure PCR Product Purification Kit" (Roche Diagnostics) according to the manufacturer's instructions. The test principle was the same as previously described for RNA extraction; the only difference concerned the lysis buffer, which was adapted for DNA products. Finally, cDNA was eluted with 50 microl elution buffer, supplemented with salmon sperm DNA (10 ng/microl final), and kept at -20degreesC.
###end p 22
###begin title 23
Real-time PCR
###end title 23
###begin title 24
Standard curve preparation
###end title 24
###begin p 25
###xml 27 35 27 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 415 418 415 418 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;11</sup>
###xml 509 512 501 504 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;12</sup>
###xml 518 521 510 513 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;15</sup>
###xml 556 557 544 545 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 569 570 557 558 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 242 247 <span type="species:ncbi:9606">human</span>
First, RNA was produced by in vitro transcription with AmpliScribe T7, T3 and SP6 High Yield Transcription Kit (Epicentre/Tebu 78610 Le Perray-en-Yvelines France) according to the manufacturer's instructions. The ORF sequence (759 pb) of the human prion gene - inserted into a pcDNA3 plasmid - was used as the reaction template. Second, four one-in-ten serial dilutions were prepared from a stock RNA solution at 10-11 grams/microl (g/microl). This yielded a standard curve with concentrations ranging from 10-12 to 10-15 g/microl, corresponding to 2.33x106 and 2.33x103copies/reaction.
###end p 25
###begin title 26
Primer Sequences
###end title 26
###begin p 27
###xml 76 82 76 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 82 86 82 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Dodelet1">[38]</xref>
###xml 193 198 <span type="species:ncbi:9606">human</span>
Primer Sequences selected for real-time PCR were those described by Dodelet et al.[38]. They ensure amplification of a fragment of 432 pb length, encompassing the M129V polymorphism within the human prion ORF.
###end p 27
###begin title 28
Quantification
###end title 28
###begin p 29
Quantification was carried out on a LightCycler by real-time PCR and SYBR Green I dye (Roche Diagnostics, Penzberg, Germany). Amplification assays were performed with 1 microl of cDNA in 20 microl final reaction mixture containing 2 microl LightCycler-FastStart DNA Master SYBR Green (Roche Diagnostics) and 0.6 microM of each primer (forward, nt 79 to 99 and reverse, nt 498 to 510). PCR conditions consisted of an initial denaturation at 95degreesC for 5 min, and 45 cycles at 95degreesC for 15 sec, 65degreesC for 5 sec, 72degreesC for 15 sec, 89degreesC for 5 sec. All samples were analyzed in duplicate. The amount of DNA was estimated after each PCR cycle by reading fluorescent dye incorporation (SYBR Green) at 530 nm in the PCR product. At the end of each run, a DNA melting step was performed and a fusion curve was recorded to control the homogeneity and specificity of the amplified DNA.
###end p 29
###begin title 30
Analysis of the results
###end title 30
###begin p 31
Readings were performed for each cycle after a fourth segment at 89degreesC, in order to exclude non-specific signal interference with the concentration calculation. Analysis was automatically performed by LightCycler software 4.0 as follows: after PCR completion, LightCycler software calculated the copy number of target molecules by plotting the logarithm of fluorescence versus cycle numbers and setting a baseline x-axis. From each sample, the baseline identified the cycle (crossing point, Ct) at which the log-linear signal could be distinguished from the background. Each run was analyzed by setting the noise band just above the background fluorescence. A value corresponding to F = 0.5 was systematically chosen for comparison between the runs. Regression of the x-axis crossing point of each standard with known concentrations defined the standard curve from which unknown samples were estimated. Specificity was achieved by plotting a melting curve graph based on the final PCR.
###end p 31
###begin title 32
129 codon Genotyping
###end title 32
###begin p 33
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 27 29 27 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">39</italic>
###xml 26 30 26 30 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Teupser1">[<italic>39</italic>]</xref>
According to Teupser et al[39] the following probe pair spans the nucleic acid sequence responsible for the polymorphism: a detection probe complementary to the 129M allele and 3'-labeled with fluorescein, and the adjoining, anchoring probe 5'-labeled with Red 640. Genotyping assays were carried out in a reaction mixture containing 10 microl of amplicons and probes, at 2.5 picomoles each per reaction. Assay conditions consisted of initial denaturation at 95degreesC for 2 min, followed by hybridization at 42degreesC for 2 min and final denaturation by increasing the series to 75degreesC at a rate of 0.1degreesC with continuous reading at 640 nm. Analysis using LightCycler was performed by creating a melting profile that defined the melting temperature (Tm) of the hybrid, composed of the target DNA and the fluorescent probe pair. Tm depends on the degree of homology between the two strands, which distinguishes M129V polymorphism. At the end of the reading, LightCycler software 4 draws a melting curve, by plotting fluorescence (F) versus temperature (T), which is automatically converted to melting peaks (-dF/dT).
###end p 33
###begin title 34
Preparation of protein lysate and PNGase F-deglycosylated protein
###end title 34
###begin p 35
###xml 33 34 33 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
All samples were prepared from 106 PBMCs according to 2 protocols:
###end p 35
###begin title 36
Protein lysate preparation only
###end title 36
###begin p 37
Cells were dissociated and incubated on ice for 30 min in a lysis buffer containing 150 mM NaCl, 0.5% triton X-100, 0.5% sodium deoxycholate and 50 mM Tris-HCl pH 7.5, and supplemented with a protease inhibitor cocktail (Roche, 82372 Penzberg Germany). After centrifugation at 450 g for 2 min, the supernatant was harvested, added to 4x loading buffer (Invitrogen, Paisley, UK), heated at 95degreesC for 5 min and stored at -80degreesC.
###end p 37
###begin title 38
Protein lysate preparation with PNGase treatment
###end title 38
###begin p 39
###xml 112 113 112 113 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
Protein lysate preparation with PNGase treatment was carried out in order to reduce the heterogeneity of the PrPC bands resulting from protein-bound Asn-linked oligosaccharides.
###end p 39
###begin p 40
Incubation for 30 min on ice was followed by protein reduction, performed by adding 1% 2-mercaptoethanol and incubating at 90degreesC for 5 min. After snap cooling on ice, 2 units of PNGase F (Roche Diagnostics) were added and digestion was carried out overnight at 37degreesC. Then, we precipitated the proteins with 3 volumes of cooled methanol for 2 hours at -20degreesC. Following centrifugation at 20,000 g for 10 min, the dry pellet was suspended in lysis buffer prior to denaturation with 4x loading buffer (Invitrogen, 95613 Cergy-Pontoise France) and heated at 95degreesC for 5 min. Finally, samples were stored at -80degreesC.
###end p 40
###begin title 41
Total protein quantification
###end title 41
###begin p 42
For all samples, we quantified the lysates for total protein by Bicinchoninic Acid Protein Assay (BCA assay, Sigma, 38297 Saint Quentin Fallavier France), before freezing, according to the manufacturer's instructions.
###end p 42
###begin title 43
###xml 20 21 20 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
Determination of PrPC levels
###end title 43
###begin p 44
###xml 63 64 63 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 119 120 119 120 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 846 847 836 837 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
"The Enzyme Immuno Assay (EIA) Kit for the determination of PrPC Protein" (SpiBio 91741 Massy France) was applied to 106 PBMCs, according to the manufacturer's instructions. Briefly, we lysed cells by solubilizing them in 65 microl of extraction buffer (10 mM Tris-HCl pH 4, 100 mM NaCl, 10 mM EDTA, 0.5% IGEPAL, and 1% Deoxycholic Acid). After spinning at 10,000 g for 5 min., the supernatant was denatured by adding 4 M Urea (final concentration, diluted in Tris-HCl 10 mM pH 7.4)) and heating at 100degreesC for 10 min. Then the EIA, based on a double-antibody sandwich principle, was performed. The micro-well plate was coated with a monoclonal antibody specific to the prion protein (aa 144-153). The detection antibody, conjugated with acetylcholinesterase (AchE), recognized the octo-repeat region located in the N-terminus part of the PrPC. Readings were performed at 414 nm.
###end p 44
###begin title 45
SDS-PAGE and Immunoblotting
###end title 45
###begin title 46
Antibodies
###end title 46
###begin p 47
###xml 528 529 528 529 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 15 20 <span type="species:ncbi:10090">mouse</span>
###xml 183 188 <span type="species:ncbi:9606">human</span>
###xml 194 199 <span type="species:ncbi:9606">human</span>
###xml 264 269 <span type="species:ncbi:9606">human</span>
###xml 368 373 <span type="species:ncbi:9606">human</span>
###xml 519 524 <span type="species:ncbi:9606">human</span>
Four different mouse antibodies were used to span large regions of PrP: SAF32 (SpiBio, 91741 Massy, France) - which recognizes an octa-repeat region located in the N-terminus part of human PrP (human numbering 79-91), 8G8 (SpiBio) - directed against an epitope of human PrP residues 95-110, 3F4 (Signet/Proteogenix, 67412 Illkirch France) - specific for an epitope of human PrP residues 109-112, and an antibody provided from ascites fluid PRI 917 (J.Grassi, CEA Saclay, France) - spanning the COOH- terminus region of human PrPC (aa: 216-221). Normalization of the expected signals was achieved using the signal obtained with monoclonal anti -alpha- tubulin (Sigma).
###end p 47
###begin title 48
SDS-PAGE and Immunoblotting
###end title 48
###begin p 49
###xml 23 24 23 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 585 590 <span type="species:ncbi:10090">mouse</span>
Protein samples (0.5 106 cells/lane i.e. 50 microg of total protein) were separated by 12% NUPAGE gel electrophoresis (Invitrogen) at 150 volts for 90 min. Proteins were then transferred to nitrocellulose membranes Hybond (Amersham biosciences, 91400 Orsay, France) for 45 min at 400 mA using the TE 22 transfer unit (Amersham biosciences). After blocking with 5% non-fat milk in PBS-0.05%Tween 20 buffer, blots were probed with the panel of selected antibodies in the dilution conditions recommended by the manufacturer. Immunoreactivity detection was carried out by a secondary anti-mouse IgG peroxydase-linked antibody, involved in an ECL reaction (ECL reagent, Amersham biosciences) and visualized on an ECL film (Amersham biosciences). Results were quantified by density readings using Sigmagel Analyzer Software (Sigma).
###end p 49
###begin p 50
###xml 219 220 219 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
We prepared five protein samples for each genotype, both with and without PNGase F treatment. Samples were then analyzed using 12% SDS-PAGE separation. We normalized the samples, by migrating lysate obtained from 0.5x106 cells - a total protein concentration of 50 microg +/- 10%/lane - and by comparing the 50 kDa signals obtained by anti -alpha- tubulin antibody blotting (not shown).
###end p 50
###begin title 51
Statistical analysis
###end title 51
###begin p 52
###xml 264 267 264 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">not</italic>
###xml 320 324 320 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">less</italic>
Statistical analysis was performed by the test of mean comparison which obeys the Student-Fisher law (from Fisher and Yates, Statistical tables for biological, agricultural and medical research, Olivier and Boyd, Edinburgh). This means that the mean difference is not significant when the calculated absolute t value is less than 0.05. If the value is greater than 0.05, this represents a difference between populations.
###end p 52
###begin title 53
Results and Discussion
###end title 53
###begin title 54
Characterization of the peripheral blood mononuclear cells
###end title 54
###begin p 55
###xml 152 153 152 153 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 211 214 211 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Prusiner2">[4]</xref>
###xml 216 220 216 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Taraboulos1">[16]</xref>
###xml 222 226 222 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Lehmann1">[17]</xref>
###xml 228 232 228 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Harris1">[35]</xref>
###xml 716 718 716 718 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 1163 1167 1163 1167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Simak1">[40]</xref>
###xml 1169 1173 1169 1173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Starke1">[41]</xref>
###xml 505 510 <span type="species:ncbi:9606">human</span>
One possible mechanism explaining the relationship between the M129V polymorphism and disease development, would be that the polymorphism influences PrPC expression and processing critical for prion propagation [4], [16], [17], [35]. We decided to test this hypothesis on peripheral blood mononuclear cells (PBMCs) for the following reasons: the controlled and ethical ease of access to PBMCs from blood donors allowed us to collect enough samples to perform a robust analysis. Collecting several hundred human samples is virtually impossible with other tissues. Secondly, as mentioned before, blood is an important issue in the context of vCJD and our results could be important to evaluate the relative risk of PrPSc transmission in different blood components. As PBMCs express the highest level of PrP compared to platelets and red blood cells the choice seemed evident even if no experimental data have showed yet that these cells could indeed propagate prions. In any case, it is not clear how the prion agent reaches the bloodstream. Theories propose local replication in specific cell types, like dendritic cells, or secretion from extra- vascular tissues [40], [41]. Finally, we hypothesized that if the M129V polymorphism exerted a more general impact on PrP expression, it could still be observed in the PBMCs.
###end p 55
###begin p 56
###xml 606 613 582 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005796-t001">Table 1</xref>
###xml 615 619 591 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Teupser1">[39]</xref>
###xml 621 625 597 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Vega1">[42]</xref>
###xml 730 734 706 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Lucotte1">[43]</xref>
Quality controls of the isolated cell population indicated systematic granulocyte contamination (10% to 15%), with an acceptable variation of 5% between samples. To determine the 129 polymorphism, we used melting curve analysis to show a specific melting peak for each genotype: 129-M/M homozygous genotype peaked at 60degreesC, V/V homozygous at 52degreesC, whereas M/V heterozygous gave 2 peaks at 52degreesC and 60degreesC. The genotype distribution of the donor population of the Languedoc region, France was 42% M/M, 42% M/V and 16% V/V, values that agree with the German and the Spanish populations (Table 1) [39], [42]. Of note, a previous study on the French population observed values of 44% M/M, 46,5% M/V and 9,5% V/V) [43]. However, this study used RFLP-PCR (Restriction Fragment Length Polymorphism-Polymerase Chain Reaction), a procedure dependent on digestion efficiency.
###end p 56
###begin title 57
M129V polymorphism distribution.
###end title 57
###begin p 58
values calculated from 50, 50, and 19 samples respectively per genotype.
###end p 58
###begin p 59
Languedoc region.
###end p 59
###begin title 60
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
PrPC expression studies
###end title 60
###begin p 61
###xml 9 11 9 11 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 37 38 37 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 50 54 50 54 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Prusiner3">[44]</xref>
###xml 71 72 71 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 148 149 148 149 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 342 343 342 343 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 354 355 354 355 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 683 690 683 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005796-t002">Table 2</xref>
###xml 945 947 945 947 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 999 1003 999 1003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Lee2">[45]</xref>
###xml 1034 1036 1034 1036 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 1599 1603 1591 1595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Xiang1">[46]</xref>
###xml 1604 1608 1596 1600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Baker2">[49]</xref>
###xml 1714 1715 1706 1707 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 2046 2048 2038 2040 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t-</italic>
###xml 2082 2083 2074 2075 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 2104 2105 2096 2097 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 2133 2140 2125 2132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005796-t002">Table 2</xref>
###xml 2220 2221 2212 2213 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 2278 2282 2270 2274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Volkel1">[50]</xref>
###xml 2447 2448 2439 2440 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 2521 2522 2513 2514 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 2607 2608 2599 2600 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 2708 2712 2700 2704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Halliday1">[51]</xref>
###xml 2143 2151 <span type="species:ncbi:9606">Patients</span>
###xml 2492 2497 <span type="species:ncbi:9940">sheep</span>
###xml 2640 2645 <span type="species:ncbi:9940">sheep</span>
Since PrPSc generation depends on PrPC expression [44], we examined PrPC expression in each of the three genotype populations. We first analyzed PrPC mRNA levels using real-time PCR amplification and SYBR Green detection for optimal sensitivity. Samples were quantified using a standard curve composed of 4 concentrations ranging from 2.33x106 to 2.33x103 copies/reaction. This agreed with the linear correlation between concentration and cycle number (correlation coefficient: 1 and slope at 3.47, indicating an acceptable PCR yield at 97%). Results from the 50 M/M, 49 M/V and 19 V/V blood samples showed no significant difference between the mRNA levels of the three populations (Table 2, observed t-value less than the 0.05 critical t-value). Nevertheless, the coefficient of variation (CV) indicated a maximum of 4 fold deviation within each group. In view of the numerous steps involved in this method and the normal variation (0.5-0.7 log10) in technologies based on the same number of steps [45], a deviation of around 0.6 log10 within each group, denoted low physiological variation. The absence of significant differences in mRNA expression between the three genotypes could indicate that transcription regulation does not relate specifically to genotype. On the other hand, gene expression profiling studies of scrapie-infected brain tissue have identified numerous genes that do modify mRNA expression. Likewise, expression of proteins encoded and involved in several pathways (e.g. inflammatory reaction, proteolysis, protease inhibition, cell grown, stress, immune responsesem leader) [46]-[49] was modified. For these reasons, we needed to confirm our results at the protein level. We determined PrPC protein levels by using a commercial EIA kit, whose N- and C-terminal antibodies detect the full-length protein. As standard curves were unavailable, we compared absorbency values expressed as Absorbency Unit (AU) for each group. Results obtained from 10 blood samples from each group revealed no statistical difference (observed t-value less than the 0.05 critical t-values) in total PrPC levels between the groups (Table 2). Patients with CJD - and other neurodegenerative diseases - show increased PrPC expression in plasma compared to healthy control groups [50]. Our findings suggest that such over-expression in plasma does not result from PBMCs. Nor does it seem to be linked with M129V polymorphism. Moreover, our total PrPC analysis conflicted with those obtained in sheep, where PBMC surface PrPC expression did depend upon the genotype. Researchers found the highest levels of PrPC in scrapie-susceptible VRQ/VRQ sheep, and the lowest levels in scrapie-resistant ARR/ARR genotypes [51].
###end p 61
###begin title 62
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
PrPC expression and processing depending on the M129V polymorphism.
###end title 62
###begin p 63
13%<VC<47%.
###end p 63
###begin p 64
3%<VC<60%.
###end p 64
###begin p 65
52%<VC<63%.
###end p 65
###begin p 66
15%<VC<20%.
###end p 66
###begin p 67
###xml 24 25 24 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 44 45 44 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
ratio diglycosylated PrPC/unglycosylated PrPC calculated by image analysis of the western blot assay performed with SAF 32, PRI 917 and 8G8 antibodies.
###end p 67
###begin p 68
###xml 36 37 36 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
ratio full length unglycosylated PrPC/C2 fragment calculated by image analysis of the western blot assay performed with 8G8 and 3F4 antibodies.
###end p 68
###begin p 69
ratio C1 fragment/C2 fragment calculated by image analysis of the western blot assay performed with PRI 917 antibody.
###end p 69
###begin title 70
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
PrPC glycosylation studies
###end title 70
###begin p 71
###xml 220 221 213 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 344 345 337 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 354 356 347 349 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 356 360 349 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Taraboulos1">[16]</xref>
###xml 362 366 355 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Lehmann1">[17]</xref>
###xml 429 430 422 423 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 526 527 519 520 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 682 688 675 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005796-g001">Fig. 1</xref>
###xml 768 769 761 762 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 879 880 872 873 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 903 907 896 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Lehmann1">[17]</xref>
###xml 1004 1005 997 998 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 1087 1093 1080 1086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005796-g001">Fig. 1</xref>
###xml 1261 1267 1254 1260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005796-g001">Fig. 1</xref>
###xml 1374 1375 1363 1364 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
The PrP protein encounters various post-translational modifications, including truncation of signalling peptides, GPI anchoring, disulfide bond formation, N-glycosylation, and alpha- and beta- physiological cleavage. PrPC is normally glycosylated at positions 182 and 198 and different paradigms show that glycans modulate the conversion of PrPC into PrPSc[16], [17]. For this reason, we investigated potential differences in PrPC glycosylation between the three genotypes by performing Western Blots (WB) before and after PrPC deglycosylation with PNGase. Before deglycosylation, both SAF32 (aa: 78-91) and 3F4 (aa: 109-112) revealed similar PrP patterns, composed of three bands (Fig. 1): a dominant 35-37 kDa band corresponding to the diglycosylated full-length PrPC, and two faint bands at 29-30 kDa and 27-28 kDa, corresponding to the monoglycosylated and unglycosylated PrPC isoforms respectively [17]. 8G8 antibody recognized two major bands- corresponding to diglycosylated and unglycosylated PrPC - and also a faint band corresponding to the monoglycosylated form (aa: 95-110) (Fig. 1). The C-terminal antibody Pri 917 (aa: 216-221) showed a major diglycosylated band, and two faint bands corresponding to monoglycosylated and unglycosylated ptoteins (Fig. 1).The alpha-tubuline signal intensity of the samples agrees with the normalization realized by using 0.5X106 cells per lane corresponding to 50 microg of total protein.
###end p 71
###begin title 72
Analysis of PrPC glycosylation.
###end title 72
###begin p 73
###xml 18 19 18 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 106 107 106 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
Immunoblots of PrPC glycoforms from the three PRNP codon 129 genotypes in PBMCs. Denatured lysates from 106 PBMCs were tested by Western Blot analysis using 4 antibodies to span the large PrP region: SAF32 (79-91), 8G8 (95-110), 3F4 (109-112) and PRI 917 (216-221). The 35-37 kDa band corresponds to the M.W. of the diglycosylated protein (D), while the 29-30 kDa and 27-28 kDa bands correspond to the M.W. of the monoglycosylated (M) and unglycosylated (U) proteins respectively. *: Non-specific signal.
###end p 73
###begin p 74
In addition, we observed on blot Pri917 a prominent band between the unglycosylated and monoglycosylated bands. We identified this band as non-specific, firstly because the Pri 917 (aa: 216-221) antibody is not purified but an ascitic fluid extract, and secondly because this band is not present in the 3F4 (aa: 109-112) and 8G8 blots (aa: 95-110). Finally, we recently ran a blot on PBMCs using the 12F10 (aa: 142-160), antibody which identified both C1 and C2 fragments. No non-specific band was detected (results not shown)
###end p 74
###begin p 75
###xml 521 528 521 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005796-t002">Table 2</xref>
###xml 730 737 730 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005796-t002">Table 2</xref>
We calculated the ratio between diglycosylated (35-37 kDa) and unglycosylated (27-28 kDa) isoforms for each sample, after quantifying SAF32 blot bands using the Sigmagel analyzer Software. We performed ratio calculations on the SAF32 blot, because we observed better resolution of low density bands with this antibody. Comparing the averages of the three ratios, from five samples of each genotype, showed no significant difference in expression (observed t-value less than the 0.05 critical t-value) between the groups (Table 2). These findings were confirmed by quantifying the Pri 917 (C-terminus region) and 8G8 blots (middle region among 3F4). Nevertheless, the absolute ratio values differed according to the antibody used (Table 2).
###end p 75
###begin title 76
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
PrPC cleavage studies
###end title 76
###begin p 77
###xml 24 25 24 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 140 144 136 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Chen1">[18]</xref>
###xml 146 150 142 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Mange1">[52]</xref>
###xml 202 206 195 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Mange1">[52]</xref>
###xml 309 312 302 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Prusiner2">[4]</xref>
###xml 390 392 383 385 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 479 481 472 474 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 750 751 743 744 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 751 755 744 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Mange1">[52]</xref>
###xml 852 858 845 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005796-g002">Fig. 2</xref>
###xml 1150 1151 1136 1137 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 1160 1166 1146 1152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005796-g002">Fig. 2</xref>
###xml 1200 1204 1186 1190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Mange1">[52]</xref>
###xml 1318 1322 1304 1308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Mange1">[52]</xref>
###xml 1451 1457 1437 1443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005796-g002">Fig. 2</xref>
In the normal brain, PrPC proteolysis generates an N-terminal truncated protein - the C1 fragment - from alpha-cleavage at position 111/112 [18], [52]. However, beta-cleavage at residue 90 can generate [52] an additional, longer C-terminal protein - the C2 fragment - that accumulates in prion-infected brain [4]. Importantly, C2 fragments correspond to protease-resistant and insoluble PrPSc. We therefore investigated potential differences in PrP cleavage that might affect PrPSc generation. Following deglycosylation, we noticed identical patterns with the different anti-PrP antibodies between the three genotypes. SAF32 (aa: 78-91) recognized a major band at 27-28 kDa, which corresponds to the estimated MW of the unglycosylated full-length PrPC[52]. As expected, with this N-terminal antibody, no truncated C-terminal forms could be identified (Fig. 2). Both 3F4 and 8G8 antibodies, whose epitopes are located between the alpha and beta cleavage sites, demonstrated similar patterns: a major 27-28 kDa unglycosylated full-length protein band and a faint band near 20 kDa corresponding to the MW of the C2 NH2-terminal truncated fragment of PrPC protein(Fig. 2). This confirms previous results [52] As expected, only the C-terminal antibody Pri 917 (aa: 216-221) identified both the C1 and C2 truncated proteins [52], at approximately 18 kDa and 20 kDa respectively. It also identified the major, unglycosylated full-length protein (27-28 kDa) (Fig. 2).
###end p 77
###begin title 78
PrPC cleavage analysis.
###end title 78
###begin p 79
###xml 133 134 133 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
Immunoblots of truncated proteins from the three PRNP codon 129 genotypes in PBMCs. After PNGase treatment, denatured lysates from 106 PBMCs were tested by Western Blot analysis using 4 antibodies to span the large PrP region: SAF32 (79-91), 8G8 (95-110), 3F4 (109-112) and PRI 917 (216-221). The 27-28 kDa band corresponds to the M.W. of the unglycosylated Full-Length (F.L.) protein, while the bands near 20 kDa and 18 kDa correspond to the C2 and C1 fragments, respectively.
###end p 79
###begin p 80
###xml 61 62 61 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 87 88 87 88 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 333 334 333 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 376 383 376 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005796-t002">Table 2</xref>
###xml 598 599 598 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 660 667 660 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005796-t002">Table 2</xref>
We calculated the ratio of the unglycosylated full-length PrPC (27-28 kDa) to the C2 NH2-terminal truncated protein for each genotype. Even though the absolute ratios from the 8G8 and 3F4 blots were slightly different, we found no significant difference between the M/M, M/V and V/V populations (five samples per genotype) (observed t-value less than 0.05) for C2 expression (Table 2). As Pri 917 antibody recognizes both C1 and C2 fragments, we also compared the C1/C2 ratios. Values for the M/M, M/V and V/V populations (five samples per genotype) showed no significant difference in expression (t-value less than 0.05) with a good coefficient of variation (Table 2).
###end p 80
###begin title 81
###xml 43 49 43 49 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005796-g003">Fig. 3</xref>
###xml 23 28 <span type="species:ncbi:9606">human</span>
Comparative study with human brain tissue (Fig. 3)
###end title 81
###begin p 82
###xml 243 250 243 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005796-g003">fig. 3A</xref>
###xml 347 354 347 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005796-g003">fig. 3B</xref>
###xml 526 530 526 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Chen1">[18]</xref>
###xml 532 536 532 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Mange1">[52]</xref>
###xml 611 612 611 612 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 959 961 959 961 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sc</sup>
###xml 1001 1005 1001 1005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Grassi1">[53]</xref>
###xml 1007 1011 1007 1011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-GonzalezRomero1">[54]</xref>
###xml 50 55 <span type="species:ncbi:9606">human</span>
###xml 908 913 <span type="species:ncbi:9606">human</span>
We observed two differences when examining normal human brain with the same antibodies (SAF32 and 3F4). First, brain tissue showed higher levels of monoglycosylated and unglycosylated isoforms (Blots SAF 32 and 3F4, respectively), than PBMCs (fig. 3A). Secondly, brain tissue showed the C2 fragment after deglycosylation more strongly than PBMCs (fig. 3B). As the antibodies recognize the same epitope, we cannot explain variations in expression by differences in antibody affinity. These findings agree with previous studies [18], [52]. Our results suggest that both the C2 fragment and under- glycosylated PrPC are under-expressed in PBMCs in comparison to brain tissue. This may result from different physiological functions or protein processing and may influence prion propagation in these tissues. We suggest that low levels of under-glycosylated isoforms and C2 fragments in PBMCs, compared to normal human brain, explains the lower blood levels of PrPSc measured when contamination does occur [53], [54].
###end p 82
###begin title 83
Comparative biochemical analysis between brain and PBMCs.
###end title 83
###begin p 84
###xml 21 22 21 22 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 81 82 81 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 518 519 518 519 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
A) Immunoblots of PrPC glycoforms from PBMCs and brain, Denatured lysates from 106 PBMCs and 10% brain were tested by Western Blot analysis using 2 antibodies: SAF32 (79-91), 3F4 (109-112). The 35-37 kDa band corresponds to the M.W. of the diglycosylated protein (D), while the 29-30 kDa and 27-28 kDa bands correspond to the M.W. of the monoglycosylated (M) and the unglycosylated (U) proteins, respectively. B) Immunoblots of truncated proteins from PBMCs and brain, After PNGase treatment, denatured lysates from 106 PBMCs and brain were tested by Western Blot analysis using 3F4 (109-112). The 27-28 kDa bands correspond to the M.W. of the unglycosylated Full-Length (F.L.) protein while the band near 20 kDa corresponds to the C2 fragment.
###end p 84
###begin p 85
###xml 227 235 227 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 235 239 235 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Alonso1">[55]</xref>
###xml 270 271 270 271 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</sup>
###xml 356 360 356 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Hosszu1">[56]</xref>
###xml 507 511 507 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Shamsir1">[57]</xref>
###xml 738 742 735 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Hosszu1">[56]</xref>
###xml 969 973 966 970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-Brandel1">[58]</xref>
###xml 975 979 972 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005796-HuillarddAignaux1">[59]</xref>
###xml 664 669 <span type="species:ncbi:9606">human</span>
###xml 747 755 <span type="species:ncbi:9606">patients</span>
###xml 794 799 <span type="species:ncbi:9606">human</span>
###xml 897 905 <span type="species:ncbi:9606">patients</span>
###xml 960 968 <span type="species:ncbi:9606">patients</span>
So, the molecular mechanism explaining the relationship between the PrP M129V genotype and disease development remains elusive. Although studies have identified some specific amino-acid interactions for the methionine genotype in vitro[55], NMR analysis indicated no PrPC instability related to M129V polymorphism that could explain disease susceptibility [56]. On the other hand, a recent study using molecular dynamic technology demonstrated a higher stability in methionine variants than valine variants [57]. In addition, a comparison of the misfolding pathway, leading to the formation of oligomeric isoforms rich in beta-sheets, revealed that methionine 129 human prion protein oligomerized more rapidly than the valine 129 variant [56]. In patients with iatrogenic CJD from contaminated human growth hormone, M129V polymorphism also influences outcome. In this case, homozygous M/M and V/V patients had a shorter incubation period than the heterozygous patients [58], [59].
###end p 85
###begin p 86
Taken together, our data suggest that in PBMCs, M129V PrP polymorphism has no significant effect on either PrP mRNA or protein expression. Neither processing nor apparent PrP glycoform distribution seem affected by this M129V polymorphism, which suggests that we should investigate its relationship with prion propagation elsewhere.
###end p 86
###begin p 87
###xml 78 83 <span type="species:ncbi:33453">Julia</span>
The authors thank Janine Viladomat for her excellent technical assistance and Julia Roche and Chantal Fournier-Wirth for reviewing the manuscript.
###end p 87
###begin title 88
References
###end title 88
###begin article-title 89
Prions and related neurological diseases.
###end article-title 89
###begin article-title 90
Genetic and infectious prion diseases.
###end article-title 90
###begin article-title 91
A new variant of Creutzfeldt-Jakob disease in the UK.
###end article-title 91
###begin article-title 92
Prions.
###end article-title 92
###begin article-title 93
Structural studies of the scrapie prion protein using mass spectrometry and amino acid sequencing.
###end article-title 93
###begin article-title 94
Purification and properties of the cellular and scrapie hamster prion proteins.
###end article-title 94
###begin article-title 95
Diversity of oligosaccharide structures linked to asparagines of the scrapie prion protein.
###end article-title 95
###begin article-title 96
Asparagine-linked glycosylation of the scrapie and cellular prion proteins.
###end article-title 96
###begin article-title 97
Glycosylinositol phospholipid anchors of the scrapie and cellular prion proteins contain sialic acid.
###end article-title 97
###begin article-title 98
Secondary structure analysis of the scrapie-associated protein PrP 27-30 in water by infrared spectroscopy.
###end article-title 98
###begin article-title 99
Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins.
###end article-title 99
###begin article-title 100
Conformational transitions, dissociation, and unfolding of scrapie amyloid (prion) protein.
###end article-title 100
###begin article-title 101
Motif-grafted antibodies containing the replicative interface of cellular PrP are specific for PrPSc.
###end article-title 101
###begin article-title 102
Pathologic conformations of prion proteins.
###end article-title 102
###begin article-title 103
Interactions and conversions of prion protein isoforms.
###end article-title 103
###begin article-title 104
Acquisition of protease resistance by prion proteins in scrapie-infected cells does not require asparagine-linked glycosylation.
###end article-title 104
###begin article-title 105
Blockade of glycosylation promotes acquisition of scrapie-like properties by the prion protein in cultured cells.
###end article-title 105
###begin article-title 106
###xml 23 28 <span type="species:ncbi:9606">human</span>
Truncated forms of the human prion protein in normal brain and in prion diseases.
###end article-title 106
###begin article-title 107
###xml 145 150 <span type="species:ncbi:10090">mouse</span>
Biochemical fingerprints of prion infection: accumulations of aberrant full-length and N-terminally truncated PrP species are common features in mouse prion disease.
###end article-title 107
###begin article-title 108
Complete genomic sequence and analysis of the prion protein gene region from three mammalian species.
###end article-title 108
###begin article-title 109
Codon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease.
###end article-title 109
###begin article-title 110
Genetic epidemiology of Creutzfeldt-Jakob disease in Europe.
###end article-title 110
###begin article-title 111
Scrapie prion proteins are synthesized in neurons.
###end article-title 111
###begin article-title 112
Developmental expression of the prion protein gene in glial cells.
###end article-title 112
###begin article-title 113
###xml 62 70 <span type="species:ncbi:9606">patients</span>
Detection and localization of PrPSc in the skeletal muscle of patients with variant, iatrogenic, and sporadic forms of Creutzfeldt-Jakob disease.
###end article-title 113
###begin article-title 114
###xml 61 66 <span type="species:ncbi:9606">human</span>
Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples.
###end article-title 114
###begin article-title 115
Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jakob disease.
###end article-title 115
###begin article-title 116
A crucial role for B cells in neuroinvasive scrapie.
###end article-title 116
###begin article-title 117
PrP expression in B lymphocytes is not required for prion neuroinvasion.
###end article-title 117
###begin article-title 118
###xml 44 49 <span type="species:ncbi:9940">sheep</span>
Transmission of BSE by blood transfusion in sheep.
###end article-title 118
###begin article-title 119
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient's death from vCJD may be linked to blood transfusion. Committee to discuss need for further precautions to prevent possible vCJD transmission through blood.
###end article-title 119
###begin article-title 120
Government confirms second case of vCJD transmitted by blood transfusion.
###end article-title 120
###begin article-title 121
An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products.
###end article-title 121
###begin article-title 122
Variant Creutzfeldt-Jakob disease: prion protein genotype analysis of positive appendix tissue samples from a retrospective prevalence study.
###end article-title 122
###begin article-title 123
Processing of a cellular prion protein: identification of N- and C-terminal cleavage sites.
###end article-title 123
###begin article-title 124
###xml 59 64 <span type="species:ncbi:9606">human</span>
Comparative analysis of normal prion protein expression on human, rodent, and ruminant blood cells by using a panel of prion antibodies.
###end article-title 124
###begin article-title 125
Distribution of cell-associated prion protein in normal adult blood determined by flow cytometry.
###end article-title 125
###begin article-title 126
###xml 28 33 <span type="species:ncbi:9606">human</span>
Prion protein expression in human leukocyte differentiation.
###end article-title 126
###begin article-title 127
Rapid detection of the prion protein M129V polymorphism with the LightCycler.
###end article-title 127
###begin article-title 128
###xml 126 131 <span type="species:ncbi:9606">human</span>
Cellular prion protein is expressed on endothelial cells and is released during apoptosis on membrane microparticles found in human plasma.
###end article-title 128
###begin article-title 129
The expression of prion protein by endothelial cells: a source of the plasma form of prion protein?
###end article-title 129
###begin article-title 130
Rapid genotyping of the M129V polymorphism of prion protein using real-time fluorescent PCR.
###end article-title 130
###begin article-title 131
The population distribution of the Met allele at the PRNP129 polymorphism (a high risk factor for Creutzfeldt-Jakob disease) in various regions of France and in West Europe.
###end article-title 131
###begin article-title 132
###xml 44 48 <span type="species:ncbi:10090">mice</span>
Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies.
###end article-title 132
###begin article-title 133
###xml 95 112 <span type="species:ncbi:11103">hepatitis C virus</span>
Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics.
###end article-title 133
###begin article-title 134
###xml 69 74 <span type="species:ncbi:10090">mouse</span>
Identification of differentially expressed genes in scrapie-infected mouse brains by using global gene expression technology.
###end article-title 134
###begin article-title 135
Gene expression profiling of scrapie-infected brain tissue.
###end article-title 135
###begin article-title 136
Unique inflammatory RNA profiles of microglia in Creutzfeldt-Jakob disease.
###end article-title 136
###begin article-title 137
Early induction of interferon-responsive mRNAs in Creutzfeldt-Jakob disease.
###end article-title 137
###begin article-title 138
###xml 91 99 <span type="species:ncbi:9606">patients</span>
Immunochemical determination of cellular prion protein in plasma from healthy subjects and patients with sporadic CJD or other neurologic diseases.
###end article-title 138
###begin article-title 139
###xml 45 50 <span type="species:ncbi:9940">sheep</span>
Expression of PrPC on cellular components of sheep blood.
###end article-title 139
###begin article-title 140
Alpha- and beta- cleavages of the amino-terminus of the cellular prion protein.
###end article-title 140
###begin article-title 141
Progress and limits of TSE diagnostic tools.
###end article-title 141
###begin article-title 142
Detection of infectious prions in urine.
###end article-title 142
###begin article-title 143
Mapping the early steps in the pH-induced conformational conversion of the prion protein.
###end article-title 143
###begin article-title 144
###xml 32 37 <span type="species:ncbi:9606">human</span>
The residue 129 polymorphism in human prion protein does not confer susceptibility to Creutzfeldt-Jakob disease by altering the structure or global stability of PrPC.
###end article-title 144
###begin article-title 145
###xml 93 98 <span type="species:ncbi:9606">human</span>
One gene, two diseases and three conformations: molecular dynamics simulations of mutants of human prion protein at room temperature and elevated temperatures.
###end article-title 145
###begin article-title 146
###xml 38 43 <span type="species:ncbi:9606">human</span>
###xml 71 79 <span type="species:ncbi:9606">patients</span>
Distribution of codon 129 genotype in human growth hormone-treated CJD patients in France and the UK.
###end article-title 146
###begin article-title 147
###xml 50 55 <span type="species:ncbi:9606">human</span>
Incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France.
###end article-title 147
###begin p 148
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 148
###begin p 149
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by the grant of Etablissement Francais du Sang (EFS2003-18). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 149

